en POLSKI
eISSN: 2083-8441
ISSN: 2081-237X
Pediatric Endocrinology Diabetes and Metabolism
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
4/2022
vol. 28
 
Share:
Share:
more
 
 
Editorial

Lipid disorders in children – an underestimated problem

Małgorzata Wójcik
1

1.
Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics, Pediatric Institute, Jagiello-nian University Medical College, Krakow, Poland
Pediatr Endocrinol Diabetes Metab 2022; 28 (4): 241–244
Online publish date: 2022/12/23
Article file
- Editorial Lipid.pdf  [0.52 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
PlumX metrics:
 
Lipid metabolism disorders (dyslipidemias) are a heterogenic group of diseases that may occur at any age, and may be tran-sient or last throughout life. They are one of the most common pathologies in the pediatric population. In the United States, ap-proximately 20% of children (age 6 to 19 years) have abnormal levels of at least one lipid parameter value [1]. A similar frequen-cy was found in the German population [2]. In adults, dyslipidemia is an established risk factor for cardiovascular disease (CVD). Because dyslipidemia often begins in childhood and adolescence, identifying children with dyslipidemia and successfully im-proving their lipid profile may reduce their risk of accelerated atherosclerosis and premature CVD [3]. Scientific evidence con-firmed the relationship between hyperlipidemia at an early age and unfavorable changes in morphology of arterial intima layer which support the hypothesis that atherosclerosis has an early onset, being a chronic and progressive process [4, 5]. There are many factors affecting lipid metabolism, including genetic background, external factors, and a combination of these. The basic classification is based on the causes of the disorders and distinguishes the following: 1. primary dyslipidemias, that are a heterogeneous group of diseases of mono, or polygenic etiology, and 2. secondary dyslipidemias resulting from the association of risk factors with external factors or other pathologies [6]. Subdivision can also be according to biochemical changes as hyper-cholesterolemia (increased total cholesterol – TC and low-density lipoprotein cholesterol [LDL-C] levels), hypertriglyceridemia (elevated triglycerides – TG), low isolated levels of high-density lipoprotein [HDL-C] cholesterol, and lastly, simultaneously in-creased TC and TG associated with low levels of HDL-C (mixed or combined) [7]. Dyslipidemia often appears as a synonym for hyperlipidemia however, hypolipidemias such as abetalipoproteinemia, familial hypobetalipoproteinemia, or sterol synthesis defects should also be considered [6]. There are 25 forms of monogenic lipid disorders described in the literature [8]. The most common monogenic conditions include familial hypercholesterolemia (FH) caused by hepatic LDL-receptor dysfunction (ap-proximately 85–90% of patients), changes in the apolipoprotein B protein receptor on the low-density lipoprotein particle sur-faces (apolipoprotein B deficit), or a gain in the proprotein convertase subtilisin/kexin type 9 function, which is involved in LDL-receptor degradation [9]. Homozygous forms are rare but present at an early age in a more severe form (overt CVD in the first–second decade of life) than heterozygous forms, illustrating a broad phenotypic spectrum [6, 10]. It is estimated, that only 5% of patients with FH in Poland are aware of their condition [11, 12]. Some patients may have a clinical phenotype similar to that of FH but without a single mutation of sufficient pathogenicity to produce it. Such patients probably have multiple gene variants, each of which makes a small independent contribution. These patients are considered to have polygenic hypercholesterolemia [13]. Regardless, the risk of early CVD is significant in both. The second most frequent genetically determined dyslipidemia is familial hypertriglyceridemia [10]. It is caused by disorders in chylomicrons or very-low-density lipoproteins (VLDL) metabo-lism. The most frequent causes dysfunction of lipoprotein lipase (95%, despite autosomal dominant transmission, a clear genetic basis is unavailable), or rarely mutations in APOC2, LMF1, GPIHBP1, and APOA5 genes [6]. It is characterized by increased TG levels in fasting (> 1000 mg/dl), that may cause acute pancreatitis, without atherosclerosis association or increased cardiovascu-lar risk [14]. The rare form of primary dyslipidemia is sitosterolemia caused by excessive plant sterol absorption at the intestine. The phenotypic spectrum ranges from almost asymptomatic individuals to severe elevated TC, development of xanthomas, premature atherosclerosis, hemolytic anemia, and macrothrombocytopenia. It is caused by biallelic mutations in either ABCG5 or ABCG8 genes, which encode the sterol efflux transporters [15]. The deficit of hepatic lipase that hydrolyzes TG and phospho-lipids in VLDL and intermediate-density lipoprotein remnants prevent their conversion to LDL-C causes an increased TC, HDL-C, and TG from adolescence [16]. The secondary causes include specific diseases and conditions that are associated with dyslipidemia. Currently, the main cause is an excessive adipose tissue mass and its pathological metabolic activity. In some cases it may be also enhanced by genetic predisposition. In an analysis of the United States National Health and Nutrition Examination Survey (NHANES) data from 1996 to 2006, the likelihood of abnormal lipid values was higher in adolescents with greater body mass index (BMI). The prevalence among youths who were normal weight, overweight (BMI 85th to 95th percentile), and obese (BMI > 95th percentile) was 14%, 22%, and 43%, respectively [17]. The main common biochemical markers are elevated levels of TG and low HDL-C, often associated with increased activity of liver aminotransferases [18]. Other secondary dyslipidemias include disease or drug related disorders. For example nephrotic syndrome, malnutrition (anorexia nervosa), cholestasis, and the following drugs: progesterone, thiazide diuretics, carbamazepine, cyclosporine or mTOR inhibitors may cause hypercholesterol-emia [6, 19]. Type 2 diabetes, kidney failure, sepsis, stress, Cushing’s syndrome, hepatitis, human immunodeficiency viral infec-tion, and the following drugs: protease inhibitors, anabolic corticosteroids, -blockers, estrogen, and thiazide diuretics are causes of hypertriglyceridemia [6]. Low HDL-C levels are associated with smoking, physical inactivity, obesity, type 2 diabetes, malnu-trition, steroids, and -blockers use [6]. The diagnosis of dyslipidemia is based on abnormal blood cholesterol, lipoprotein and/or TG test results. In practice, this is difficult in children and adolescents, because the parameters values may change with age. In-terpretation of cholesterol and lipoprotein determinations in the first 2 years of life is particularly difficult because serum TC and LDL-C levels are lower during intrauterine life and shortly after birth, but increase rapidly during the first week of life, and then gradually up to 2 years of age, then they remain relatively constant until adolescence, and then decrease, before rising in the late teenage years [10, 20–22]. Lipid levels are also affected by gender and ethnicity. For example males experience a decrease in HDL-C level during late puberty, while in females it remains stable until menopause [7, 13]. African American children have high-er TC and HDL-C levels and lower TG levels compared with other racial/ethnic groups [13]. Therefore, lipid abnormalities in the pediatric age group should be identified based on the percentile thresholds [23]. Apart from the difficulties mentioned above, it is worth noting, that contrary to adults, proposed cutoff points for children have not been validated as accurate predictors for ac-celerated atherosclerosis or CVD events. Because most lipid disorders in children are asymptomatic, their diagnosis is most often based only on blood tests. There are two approaches to the diagnosis of lipid disorders: universal screening strategy or directed to the family or individual risk factors in asymptomatic patients. Taking into account the risks associated with the under detec-tion of lipid disorders in childhood, but also all the above mentioned limitations of diagnostic methods, most experts currently support selective screening as the best diagnostic method. On the other hand, taking into account the low effectiveness of screen-ing tests in adults (e.g. currently in Poland live about 20 million people with hypercholesterolemia, and the vast majority of them is not diagnosed), universal screening tests in children / adolescents can be seriously considered. [11, 12]. Selective screening should be performed on children/adolescents over 2 years old with family or individual risk factors (overweight/obesity, hyper-tension, smoking, sedentary life, or diabetes as soon as these factors are identified and regularly while present with 2 or 3 years interval) [6, 10]. Screening can be at fast or postprandial (TG level is higher postprandial) but must be confirmed in two fasting samples if altered. The average between these two values can be used for diagnostic and therapeutic purposes [7, 10, 24]. In all cases of dyslipidemias lifestyle changes are recommended, with a particular incidence of dietary treatment and increase of phys-ical activity, and avoiding smoking [7]. In hypercholesterolemia the dietary intervention may include supplementation with stanols and plant sterols, substances structurally similar to cholesterol that inhibit their intestinal absorption. Supplemented commercial products have variable concentrations and can be used as co-adjuvants in lowering LDL-C (approximately 8% re-duced TC) [25]. As demonstrated by Grabarczyk et al. in a recently published paper in Pediatric Endocrinology Diabetes and Metabolism 2022; 28 (2), correctly selected dietary supplements may be an alternative to statins with an equally effective effect in selected pediatric patients [26]. Dietary restrictions of hypercholesterolemia are not indicated below 2 years of age due to the increased need for dietary fats critical for the growth and development of the nervous system [25]. In hypertriglyceridemia, the initial dietary approach includes decreased sugar and saturated fat consumption, and increase of fish intake (rich in -3) [25]. The pharmacological options are several and must be selected according to the lipid profile and risk-benefit. It should be consid-ered according to CVD risk stratification. Evidence establishing the long-term effectiveness of lipid-lowering interventions in children comes largely from studies in children with FH, a group at high risk for morbidity and early mortality. Statins that inhib-it the reductase of 3-hydroxy-3-methylglutaryl- coenzyme-A, an enzyme that limits endogenous cholesterol synthesis with de-creased intracellular cholesterol content and increased LDL-C clearance, have been the predominate agent utilized in clinical practice. Therapy with statins in children with FH decelerates the atherosclerosis process, as assessed by subclinical vascular findings (e.g, carotid intima-media thickness). However long-term outcome data on cardiovascular morbidity and mortality are not available for the general pediatric population. Despite that, current studies suggest that for the most beneficial effect statin treatment it should be started in childhood. Delay of the treatment can cause future CVD development. There is growing scien-tific evidence that statin therapy in pediatric patients is safe and effective [7, 26, 27]. Statin therapy may be initiated in children ≥ 10 years of age (except for children with FH, in whom the Forum of Lipid Experts in Poland recommends the use of statins > 8 years of age (accumulating data support lowering of this age even to 6 years), and in children with homozygous FH < 8 years of age with LDL-C concentration > 500 mg/dl (12.9 mmol/l)) [10]. Cholesterol absorption inhibitors (ezetimibe), that inhibit intes-tinal cholesterol absorption from plant sterols, can be used from 10 years of age in children with FH and/or high-risk factors for premature CVD, who do not reach therapeutic goals with the optimized statin dose [14, 28]. In the most severe forms of homo-zygous FH, that usually poorly respond to standard treatment options, lipoprotein apheresis is an additional option for these pa-tients; however, its effect on LDL-C concentrations is temporary and have to be repeated every 1–2 weeks [28]. Moreover, as noted by the authors of a recent study in Pediatric Endocrinology Diabetes and Metabolism (Grabarczyk et al. 2022; 28 (2)), in children with dyslipidemia, regardless of its background, statin therapy is the most effective in lowering LDL-C [26]. In recent years novel lipid-lowering drugs have been implemented. Currently, they are approved for patients with severe familial hyper-cholesterolemia. The possibilities of their use in children are currently limited and require further research [6, 28]. In 2021, the Food and Drug Administration (FDA) in United States, and the European Medicine Agency (EMA) approved evinacumab (fully humanized anti- Angiopoietin-like protein 3 antibody) as an add-on therapy for patients over 12 years of age with homozygous FH [29]. In 2021 and 2022 FDA and the EMA respectively approved evolocumab (human monoclonal antibody that inhibits PCSK9) for children above 10 years of age with primary homozygous FH [30]. Recently Ziółkowska et al. presented a detailed, current description of the pharmacotherapy currently used in FH, as well as the drugs undergoing suitability assessment, in the paper published in Pediatric Endocrinology Diabetes and Metabolism 2022; 28 (2) [31]. In familial hypertriglyceridemia drugs are less effective than low-fat diet. Fibrates, that are agonists of nuclear PPAR-α receptors and favor TG and VLDL degradation, are only indicated in children with severe hypertriglyceridemia (> 500 mg/dl) or at risk of pancreatitis, who are unresponsive to dietary measures [14]. In combined hyperlipidemia associated with excessive body mass, the treatment should be concentrated on healthy habits implementation, that involves greater fruit and vegetable consumption, adequate water consumption, and dai-ly physical activity, coupled with reduced consumption of sugary foods and drinks [25]. Lipid disorders in children are underdi-agnosed and underestimated. There is still no direct evidence that their treatment reduces adult CVD mortality. But based on the indirect evidence there is a common belief that treatment should be started in childhood, and that early diagnosis and treatment may have long-term benefits.

References

1. Dai S, Yang Q, Yuan K, et al. Non−High-Density Lipoprotein Cholesterol: Distribution and Prevalence of High Serum Levels in Children and Adolescents: United States National Health and Nutrition Examination Surveys, 2005-2010. J Pediatr 2014; 164: 247–253. doi: 10.1016/j.jpeds.2013.08.069.
2. Dathan-Stumpf A, Vogel M, Hiemisch A, et al. Pediatric reference data of serum lipids and prevalence of dyslipidemia: Results from a population-based cohort in Germany. Clin Biochem 2016; 49: 740–749. doi: 10.1016/j.clinbiochem.2016.02.010.
3. Drozdz D, Alvarez-Pitti J, Wójcik M, et al. Obesity and Cardiometabolic Risk Factors: From Childhood to Adulthood. Nutrients 2021; 13: 4176. doi: 10.3390/nu13114176.
4. Berenson GS, Srinivasan SR, Bao W, et al. Association between Multiple Cardiovascular Risk Factors and Atherosclerosis in Children and Young Adults. N Eng J Med 1998; 338: 1650–1656. doi: 10.1056/NEJM199806043382302.
5. Cheung CL, Cheung BMY. Predictors of Carotid Atherosclerosis in Young Adults: Insights From the Bogalusa Heart Study. J Am Heart Assoc 2021; 10 (12): e021887. doi: 10.1161/JAHA.121.021887.
6. Mosca S, Araújo G, Costa V, et al. Dyslipidemia Diagnosis and Treatment: Risk Stratification in Children and Adolescents. J Nutr Metab 2022; 2022: 1–10. doi: 10.1155/2022/4782344.
7. de Ferranti SD, Newburger JW. Dyslipidemia in Children: Management. UpToDate, Waltham, MA, USA 2020;
8. Hegele RA, Borén J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol 2020; 8: 50–67. doi: 10.1016/S2213-8587(19)30264-5
9. Sturm AC, Knowles JW, Gidding SS, et al. Clinical Genetic Testing for Familial Hypercholesterolemia. J Am Coll Cardiol 2018; 72: 662–680. doi: 10.1016/j.jacc.2018.05.044.
10. Myśliwiec M, Walczak M, Małecka-Tendera E, et al. Management in familial hypercholesterolaemia in children and adolescents. Position of the Lipid Expert Forum. Kardiol Pol 2013; 71: 1099–1105. doi: 10.5603/KP.2013.0276.
11. Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci 2021; 17: 1447–1547. doi: 10.5114aoms/141941.
12. Zdrojewski T, Solnica B, Cybulska B, et al. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol 2016; 74: 213–223. doi: 10.5603/KP.2016.0029.
13. de Ferranti SD, Newburger JW. Dyslipidemia in children and adolescents: Definition, screening, and diagnosis. UpToDate, Waltham, MA, USA. 2020;
14. Elkins C, Fruh S, Jones L, Bydalek K. Clinical Practice Recommendations for Pediatric Dyslipidemia. Journal of Pediatric Health Care 2019; 33: 494–504. doi: 10.1016/j.pedhc.2019.02.009.
15. Yoo EG. Sitosterolemia: a review and update of pathophysiology, clinical spectrum, diagnosis, and management. Ann Pediatr Endocrinol Metab 2016; 21: 7–14. doi: 10.6065/apem.2016.21.1.7.
16. Berberich AJ, Hegele RA. The complex molecular genetics of familial hypercholesterolaemia. Nat Rev Cardiol 2019; 16: 9–20. doi: 10.1038/s41569-018-0052-6.
17. Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths – United States, 1999-2006. MMWR Morb Mortal Wkly Rep 2010; 59: 29–33.
18. Wójcik M, Ruszała A, Szczudlik E, et al. Shall we diagnose metabolic syndrome in adolescents? Neuro Endocrinol Lett 2018; 39: 130–134.
19. White M, Haddad H, Leblanc MH, et al. Conversion From Cyclosporine Microemulsion to Tacrolimus-Based Immunoprophylaxis Improves Cholesterol Profile in Heart Transplant Recipients With Treated but Persistent Dyslipidemia: The Canadian Multicentre Randomized Trial of Tacrolimus vs Cyclosporine Microemulsion. The Journal of Heart and Lung Transplantation 2005; 24: 798–809. doi: 10.1016/j.healun.2004.05.023.
20. Jolliffe CJ, Janssen I. Distribution of Lipoproteins by Age and Gender in Adolescents. Circulation 2006; 114: 1056–1062. doi: 10.1161/CIRCULATIONAHA.106.620864.
21. Kwiterovich PO. Recognition and Management of Dyslipidemia in Children and Adolescents. J Clin Endocrinol Metab 2008; 93: 4200–4209. doi: 10.1210/jc.2008-1270.
22. Goldberg AC, Hopkins PN, Toth PP, et al.. J Clin Lipidol 2011; 5 (3 Suppl): S1–S8. doi: 10.1016/j.jacl.2011.04.003.
23. Daniels SR, Greer FR. Lipid Screening and Cardiovascular Health in Childhood. Pediatrics 2008; 122: 198–208. doi: 10.1542/peds.2008-1349.
24. Lobstein T, Baur L, Uauy R. Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients. Obesity in children and young people: a crisis in public health. Obes Rev 2004; 5: 4–85.
25. Williams L, Baker-Smith CM, Bolick J, et al. Nutrition interventions for youth with dyslipidemia: a National Lipid Association clinical perspective. J Clin Lipidol 2022; doi: 10.1016/j.jacl.2022.07.011.
26. Grabarczyk M, Pomianowska K, Zaręba-Głód T, et al. Statin therapy and lipids-lowering supplements – safe and effective treatment of lipids disturbances in children. Pediatr Endocrinol Diabetes Metab 2022; 28: 108–113. doi: 10.5114/pedm.2022.116114.
27. Hennig M, Brandt-Varma A, Wołoszyn-Durkiewicz A, et al. Monitoring the Effects of Hypolipidemic Treatment in Children with Familial Hypercholesterolemia in Poland. Life 2020; 10: 270. doi: 10.3390/life10110270.
28. Fiorentino R, Chiarelli F. Treatment of Dyslipidaemia in Children. Biomedicines 2021; 9: 1078. doi: 10.3390/biomedicines9091078.
29. Surma S, Romańczyk M, Filipiak KJ. Evinacumab – an ANGPTL3 inhibitor; a new drug in the treatment of lipid disorders. Review on the literature and clinical studies. Folia Cardiol 2021; 16: 30–39.
30. https://www.ema.europa.eu/en/documents/overview/repatha-epar-medicine-overview_en.pdf. (access Nov 6th 2022)
31. Ziółkowska S, Kijek N, Zendran I, et al. Familial hypercholesterolemia – treatment update in children, systematic review. Pediatr Endocrinol Diabetes Metab 2022; 28: 152–161. doi: 10.5114/pedm.2022.116112.

Quick links
© 2023 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.